Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
Thrombosis & Haemostasis Journal (TH Open) has recently shared a promising data on Emicizumab efficacy on X:
”Implementing an Assay to detect Anti-drug Antibody against Emicizumab: Experience from One Center in France. Auditeau et al. evaluated the effectiveness of a modified bridging ELISA in detecting anti-drug antibodies.”
Read the full article here.
A bispecific antibody mimicking factor VIII, is approved for prophylaxis in hemophilia A — but what could possibly go wrong with a drug designed to work perfectly?
Although rare, anti-drug antibodies (ADA) can reduce its efficacy,using data from One center in France.
The study by Claire Auditeau et al. aimed to investigate potential causes behind the loss of Emicizumab efficacy.
Using a modified bridging ELISA, ADA was detected in two patients—one newly identified with a neutralizing ADA that blocked Emicizumab’s binding to factors IX and X.
In ADA-negative cases, bispecific antibody’s levels improved following adherence adjustments.
The findings suggest that the assay may help distinguish ADA-related loss of efficacy from non-immunologic causes in patients with unexplained bleeding.
Updates on thrombosis and hemostasis field advancements featured in Hemostasis Today.
-
Aug 26, 2025, 10:02Women’s Equality Day: HFA Recognizes Women with Bleeding Disorders
-
Aug 26, 2025, 09:59Rare Disease Advisor – RBC Rheology Alterations in Hemophilia with Arthropathy
-
Aug 26, 2025, 09:57HFA Supports Future Planning for People with Bleeding Disorders
-
Aug 26, 2025, 09:56Phillip Taboada: TXA Shows No Added Benefit in Aquablation
-
Aug 26, 2025, 09:50A Global Collaboration: PERT Consortium Expands Reach in PE Care
-
Aug 26, 2025, 09:54TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
-
Aug 26, 2025, 09:38Advancing CAT Care: New Insights on Extended Anticoagulation from Gerotziafas and Tafur
-
Aug 26, 2025, 09:35Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
-
Aug 25, 2025, 10:40Maria Filomena Ruberto on The Hypercoagulable State
-
Aug 25, 2025, 09:19Parham Dastjerdi – Clonal Hematopoiesis and VTE Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!